7 March 2025 - In head to head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and further decreased sweat chloride compared to ivacaftor/tezacaftor/elexacaftor in combination with ivacaftor.

Vertex Pharmaceuticals announced today that the UK MHRA has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once daily next in class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene.

Read Vertex Pharmaceuticals press release